Dysregulation of mTORCl/mTORC2 pathway is observed in many cancers and mTORC1 inhibitors have been used clinically in many tumor types;however,the mechanism of mTORC2 in tumorigenesis is still obscure.Here,we mainly e...Dysregulation of mTORCl/mTORC2 pathway is observed in many cancers and mTORC1 inhibitors have been used clinically in many tumor types;however,the mechanism of mTORC2 in tumorigenesis is still obscure.Here,we mainly explored the potential role of mTORC2 in esophageal squamous cell carcinoma(ESCC)and its effects on the sensitivity of cells to mTOR inhibitors.We demonstrated that RICTOR,the key factor of mTORC2,and p-AKT(Ser473)were excessively activated in ESCC and their overexpression is related to lymph node metastasis and the tumor-node-metastasis(TNM)phase of ESCC patients.Furthermore,we found that mTORCl/mTORC2 inhibitor PP242 exhibited more efficacious anti-proliferative effect on ESCC cells than mTORC1 inhibitor RAD001 due to RAD001-triggered feedback activation of AKT signal.Another,we demonstrated that down-regulating expression of RICTOR in ECa109 and EC9706 cells inhibited proliferation and migration as well as induced cell cycle arrest and apoptosis.Noteworthy,knocking-down stably RICTOR significantly suppresses RAD001-induced feedback activation of AKT/PRAS40 signaling,and enhances inhibition efficacy of PP242 on the phosphorylation of AKT and PRAS40,thus potentiates the antitumor effect of RAD001 and PP242 both in vitro and in vivo.Our findings highlight that selective targeting mTORC2 could be a promising therapeutic strategy for future treatment of ESCC.展开更多
In the case presented here, everolimus was administered after first line therapy with sunitinib in a patient with metastatic renal cell carcinoma. The safety profile was excellent. The prolonged progression-free survi...In the case presented here, everolimus was administered after first line therapy with sunitinib in a patient with metastatic renal cell carcinoma. The safety profile was excellent. The prolonged progression-free survival(PFS) obtained with everolimus in this case is of peculiar interest, as it is a multiple of the median PFS obtained in with everolimus in the regulatory trial. Such finding suggests that a subset of patients with renal cell carcinma may particularly benefit from everolimus.展开更多
基金supported by the Open Foundation Project of Pharmacy in Zhejiang Province,China(Grant No.YKFJ2-010)the National Natural Science Foundation of Henan Province,China(Grant No.182300410312)+2 种基金Henan Provincial University Science and Technology Innovation Team,Department of Education of Henan Province(Grant No.19IRTSTHN001,China)Key Research Project of University,Department of Education of Henan Province(Grant No.20A350019,China)the National Science and Technology Major Project of China(Grant No.2018ZX10302205)
文摘Dysregulation of mTORCl/mTORC2 pathway is observed in many cancers and mTORC1 inhibitors have been used clinically in many tumor types;however,the mechanism of mTORC2 in tumorigenesis is still obscure.Here,we mainly explored the potential role of mTORC2 in esophageal squamous cell carcinoma(ESCC)and its effects on the sensitivity of cells to mTOR inhibitors.We demonstrated that RICTOR,the key factor of mTORC2,and p-AKT(Ser473)were excessively activated in ESCC and their overexpression is related to lymph node metastasis and the tumor-node-metastasis(TNM)phase of ESCC patients.Furthermore,we found that mTORCl/mTORC2 inhibitor PP242 exhibited more efficacious anti-proliferative effect on ESCC cells than mTORC1 inhibitor RAD001 due to RAD001-triggered feedback activation of AKT signal.Another,we demonstrated that down-regulating expression of RICTOR in ECa109 and EC9706 cells inhibited proliferation and migration as well as induced cell cycle arrest and apoptosis.Noteworthy,knocking-down stably RICTOR significantly suppresses RAD001-induced feedback activation of AKT/PRAS40 signaling,and enhances inhibition efficacy of PP242 on the phosphorylation of AKT and PRAS40,thus potentiates the antitumor effect of RAD001 and PP242 both in vitro and in vivo.Our findings highlight that selective targeting mTORC2 could be a promising therapeutic strategy for future treatment of ESCC.
文摘In the case presented here, everolimus was administered after first line therapy with sunitinib in a patient with metastatic renal cell carcinoma. The safety profile was excellent. The prolonged progression-free survival(PFS) obtained with everolimus in this case is of peculiar interest, as it is a multiple of the median PFS obtained in with everolimus in the regulatory trial. Such finding suggests that a subset of patients with renal cell carcinma may particularly benefit from everolimus.
